Details for Patent: 9,861,632

Title:	Methods and compositions for safe and effective treatment of erythema
Abstract:	Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
Inventor(s):	Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Hegenheim, FR), Freidenreich; Philip (Yardley, PA), Liu; Yin-sang (Princeton Junction, NJ), Leoni; Matthew James (Titusville, NJ)
Assignee:	Galderma Laboratories, L.P. (Fort Worth, TX)
Filing Date:	Dec 14, 2015
Application Number:	14/968,104
Claims:	1. A method of treating facial erythema associated with rosacea in a subject in need thereof without causing unacceptable drug related adverse events, comprising once daily topically administering to a skin area of the subject affected by the facial erythema a topical composition comprising, relative to the total weight of the composition: 0.5% by weight of brimonidine tartrate; about 8.0% to about 30.0% by weight in total of at least one polyol; about 0.20% to about 4.0% by weight of a gelling agent; and a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein the topical composition comprises about 0.5% to about 2.0% by weight of the gelling agent. 3. The method of claim 2, wherein the gelling agent comprises a carbomer. 4. The method of claim 3, wherein the carbomer is selected from the group consisting of carbomer 934P, carbomer 974P, and carbomer 980. 5. The method of claim 4, wherein the topical composition comprises a first polyol and a second polyol, and the amount of each of the first and second polyols in the composition is independently about 4 to 15% by weight relative to the total weight of the composition. 6. A method of treating facial erythema associated with rosacea in a subject in need thereof without causing unacceptable drug related adverse events, comprising once daily topically administering to a skin area of the subject affected by the facial erythema a topical composition comprising, relative to the total weight of the composition: 0.5% by weight of a brimonidine tartrate; about 5.0% to about 15.0% by weight of at least one polyol; about 0.5% to about 2.0% by weight of a gelling agent; and a pharmaceutically acceptable carrier, wherein the gelling agent comprises a carbomer selected from the group consisting of carbomer 934P, carbomer 974P, and carbomer 980. 7. The method of claim 6, wherein the topical composition further comprises a preservative selected from the group consisting of sodium benzoate, phenoxyethanol, benzyl alcohol, methylparaben, imidazolidinyl urea and diazolidinyl urea.